Pfizer Inc. (NYSE:PFE) Shares Purchased by Allied Investment Advisors LLC

Allied Investment Advisors LLC increased its position in Pfizer Inc. (NYSE:PFE - Free Report) by 15.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 303,884 shares of the biopharmaceutical company's stock after purchasing an additional 41,147 shares during the quarter. Allied Investment Advisors LLC's holdings in Pfizer were worth $7,700,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer during the 4th quarter valued at $26,000. Clarity Asset Management Inc. purchased a new position in shares of Pfizer in the 4th quarter valued at about $27,000. Gould Capital LLC increased its stake in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares in the last quarter. Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer during the 4th quarter worth approximately $28,000. Finally, Bernard Wealth Management Corp. purchased a new stake in Pfizer during the 4th quarter worth approximately $30,000. Institutional investors own 68.36% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on PFE. Citigroup restated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 price objective (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, Cantor Fitzgerald started coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective on the stock. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Stock Down 0.4%

Pfizer stock traded down $0.09 during midday trading on Tuesday, reaching $23.37. The company's stock had a trading volume of 35,148,276 shares, compared to its average volume of 41,025,196. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a market cap of $132.85 billion, a P/E ratio of 16.57, a P/E/G ratio of 0.64 and a beta of 0.58. The business has a 50-day simple moving average of $23.08 and a 200-day simple moving average of $25.04.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. During the same period last year, the firm earned $0.82 earnings per share. Pfizer's quarterly revenue was down 7.8% on a year-over-year basis. On average, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.36%. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.